ARS Pharma stockholders elect Class III directors, ratify EY, approve say-on-pay

ARS Pharmaceuticals, Inc.

Saqib Islam, Phillip Schneider, Laura Shawver elected as Class III directors; Schneider received 38.5M for vs 27.5M withheld.
Ernst & Young ratified as auditor for FY2026 with 79.5M for, 102k against.
Advisory vote on NEO compensation approved with 57.3M for, 8.1M against, 622k abstain.
Advisory vote selects 1-year frequency for future say-on-pay votes (52.1M votes) until 2032 meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.